Anika Therapeutics commenced the U.S. commercial soft launch of TACTOSET bone repair therapy. TACTOSET is developed to treat bone voids and other bone defects of the skeletal system caused by trauma or age-related degeneration. This is Anika’s first product to launch under its U.S.-based hybrid commercial model.
TACTOSET also represents the company’s first surgically-delivered regenerative therapy in the U.S. for bone repair procedures. It is an injectable, hyaluronic acid-enhanced, osteoconductive calcium phosphate bone substitute. The kit comprises an aqueous solution in a pre-loaded syringe and a dry powder that must be mixed intra-operatively using the supplied mixing system to form a paste prior to use.
Joseph Darling, President and Chief Executive Officer of Anika Therapeutics, said “We believe our hybrid commercial model provides us with a direct line of sight into the market, enabling Anika to achieve rapid market penetration with TACTOSET, while avoiding the significant investment associated with building a large direct sales force internally.”
The hybrid model will allow the product to launch in various phases and to scale where appropriate, as TACTOSET is introduced across multiple categories in the orthopedic segment. The commercial team gains more precise commercial control, including greater visibility on product demand, end-user activity and fulfillment.
Anika Therapeutics commenced the U.S. commercial soft launch of TACTOSET bone repair therapy. TACTOSET is developed to treat bone voids and other bone defects of the skeletal system caused by trauma or age-related degeneration. This is Anika’s first product to launch under its U.S.-based hybrid commercial model.
TACTOSET also represents the...
Anika Therapeutics commenced the U.S. commercial soft launch of TACTOSET bone repair therapy. TACTOSET is developed to treat bone voids and other bone defects of the skeletal system caused by trauma or age-related degeneration. This is Anika’s first product to launch under its U.S.-based hybrid commercial model.
TACTOSET also represents the company’s first surgically-delivered regenerative therapy in the U.S. for bone repair procedures. It is an injectable, hyaluronic acid-enhanced, osteoconductive calcium phosphate bone substitute. The kit comprises an aqueous solution in a pre-loaded syringe and a dry powder that must be mixed intra-operatively using the supplied mixing system to form a paste prior to use.
Joseph Darling, President and Chief Executive Officer of Anika Therapeutics, said “We believe our hybrid commercial model provides us with a direct line of sight into the market, enabling Anika to achieve rapid market penetration with TACTOSET, while avoiding the significant investment associated with building a large direct sales force internally.”
The hybrid model will allow the product to launch in various phases and to scale where appropriate, as TACTOSET is introduced across multiple categories in the orthopedic segment. The commercial team gains more precise commercial control, including greater visibility on product demand, end-user activity and fulfillment.
Copy to clipboard 
